reports
Pineapple Resources Berhad: 1 director
A director at Pineapple Resources Berhad bought 266,950 shares at 0.700MYR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
TC Energy to issue first quarter 2024 results on May 3 and hold annual...
TC Energy to issue first quarter 2024 results on May 3 and hold annual and special meeting of common shareholders on June 4 CALGARY, Alberta, April 16, 2024 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will release its first quarter 2024 financial results on Friday, May 3, 2024 pre-market and hold its 2024 annual and special meeting of common shareholders on Tuesday, June 4, 2024, at 8 a.m. MDT / 10 a.m. EDT. First quarter 2024 financial resultsFrançois Poirier, TC Energy President and Chief Executive Officer, Joel Hunter, Executive Vice-President...
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics Provides SAB-142 Trial Update MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of serum sickness thus far. In October 2023, SAB rec...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targe...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver....
- Virginia Romero
NATURGY: CRITERIA CONFIRMA QUE MANTIENE CONVERSACIONES CON UN POTENCIA...
Criteria Caixa, en reacción a los rumores de esta mañana que apuntaban a que un grupo emiratí (Adnoc) estaría negociando la compra del 40% del capital de NTGY en manos de GIP y CVC, ha comunicado a la CNMV que reafirma su compromiso como inversor a largo plazo con el proyecto industrial de NTGY
Director/PDMR Shareholding
Director/PDMR Shareholding TORONTO, ONTARIO, April 16, 2024 (GLOBE NEWSWIRE) -- (“Amaroq Minerals” or the “Company”) Director/PDMR Shareholding - Notification of Transactions of Directors/Persons Discharging Managerial Responsibilities (PDMRs) TORONTO, ONTARIO – April 16, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ) announces that on April 15, 2024, it was informed that Livermore Partners LLC, a company in which David Neuhauser, Non-Executive Director of Amaroq Minerals, is Managing Director, acquired a total of 19,200 common shares of no par value in the Company. This ...
Edison issues review on Tetragon Financial Group (TFG): FY23 growth dr...
Edison Investment Research Limited Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors 16-Apr-2024 / 12:07 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 16 April 2024 Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors Tetragon Financial Group (Tetragon) posted a 6.4% net asset value (NAV) per share total return in US dollar terms in FY23. Tetragon’s returns normally have a low correlation with broader markets, and therefore its FY23 pe...
- Felix Fischer
Lucror Analytics - Morning Views Latam
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar. To request full and unrestricted access to Lucror’s research and analytics platform, please visit
Moody's Ratings rates Thrasio's DIP facilities B1 and Caa1
Moody's Ratings assigned a B1 rating to the $90 million senior secured super priority debtor-in-possession (DIP) new money term loan (NMTL) and a rating of Caa1 to the $270 million senior secured super priority DIP rollup term loan (RUTL) of Thrasio, LLC (DIP) (Thrasio). There is no outlook on the f...
Divfex Berhad: 1 director
A director at Divfex Berhad sold 4,870,000 shares at 0.133MYR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
KRM22: 1 director
A director at KRM22 bought 100,000 shares at 25p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
Zhongzhi Pharmaceutical Holdings Limited: 1 director
A director at Zhongzhi Pharmaceutical Holdings Limited bought 2,259,000 shares at 1.170HKD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.